M. Craig Shepherd is a Senior Managing Director in Blackstone Life Sciences and a member of its Investment Committees. Since joining Blackstone in New York in 2017, Mr. Shepherd has played a leadership role in Blackstone’s acquisition of Clarus, the creation of Blackstone Life Sciences Yield, and Blackstone’s investments in Alnylam Pharmaceuticals, Axsome Therapeutics, Elanco (Tarsus royalties), Harmony Biosciences, PTC Therapeutics, Amicus Therapeutics, Sutro Biopharma (Vaxcyte royalties) and various others.

Prior to Blackstone, Mr. Shepherd worked at another life sciences private equity firm and at Amgen, where he held various roles at Amgen’s global HQ in California and its international HQ in Switzerland.

Mr. Shepherd holds an MBA from Harvard Business School, a law degree from McGill University, and a BA from the University of Western Ontario. Mr. Shepherd has served on the boards of various business and non-profit organizations, including the Tufts University Parents Leadership Council, the American Kidney Fund, the Healthcare Advisory Board of the Partnership Fund for New York City and the McGill University Chancellor’s Advisory Board. A past recipient of the Terry Fox Humanitarian Award, Mr. Shepherd now serves on the program's board.